Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM
Quantum BioPharma (NASDAQ:QNTM) announces its dual listing on Upstream, a MERJ Exchange market and global securities trading app, starting January 14, 2025, at 10:00am EST. The company, focused on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, will maintain its listings on Nasdaq, Canadian Securities Exchange, and Frankfurt exchanges.
The Upstream platform operates 20 hours daily, offering real-time trading and settlement with transparent orderbook features. Non-U.S. investors can access QNTM shares through the Upstream app after completing KYC verification. Trading will begin once an existing shareholder places a sale offer.
CEO Zeeshan Saeed states this dual listing aims to add value and liquidity while expanding their reach to a global investor base. U.S. persons are restricted from depositing, buying, or selling securities on Upstream.
Quantum BioPharma (NASDAQ:QNTM) annuncia la sua doppia quotazione su Upstream, un mercato MERJ Exchange e app globale per il trading di titoli, a partire dal 14 gennaio 2025, alle 10:00 EST. L'azienda, focalizzata sullo sviluppo di trattamenti per disturbi neurodegenerativi, metabolici e da abuso di alcol, manterrà le sue quotazioni su Nasdaq, Canadian Securities Exchange e sui mercati di Francoforte.
La piattaforma Upstream opera 20 ore al giorno, offrendo trading e liquidazione in tempo reale con funzionalità di orderbook trasparenti. Gli investitori non statunitensi possono accedere alle azioni QNTM tramite l'app Upstream dopo aver completato la verifica KYC. Il trading partirà non appena un azionista esistente effettuerà un'offerta di vendita.
Il CEO Zeeshan Saeed afferma che questa doppia quotazione ha l'obiettivo di aggiungere valore e liquidità, ampliando al contempo il loro raggio d'azione a una base di investitori globale. Le persone negli Stati Uniti sono escluse dal depositare, acquistare o vendere titoli su Upstream.
Quantum BioPharma (NASDAQ:QNTM) anuncia su doble cotización en Upstream, un mercado de MERJ Exchange y aplicación global de operaciones de valores, a partir del 14 de enero de 2025, a las 10:00 a.m. EST. La empresa, centrada en desarrollar tratamientos para trastornos neurodegenerativos, metabólicos y de abuso de alcohol, mantendrá sus cotizaciones en Nasdaq, Canadian Securities Exchange y en las bolsas de Frankfurt.
La plataforma Upstream opera 20 horas al día, ofreciendo negociación y liquidación en tiempo real con características de libro de órdenes transparentes. Los inversores no estadounidenses pueden acceder a las acciones de QNTM a través de la aplicación Upstream una vez completada la verificación KYC. La negociación comenzará una vez que un accionista existente realice una oferta de venta.
El CEO Zeeshan Saeed afirma que esta doble cotización tiene como objetivo agregar valor y liquidez mientras se amplía su alcance a una base de inversores global. Las personas de EE. UU. tienen restricciones para depositar, comprar o vender valores en Upstream.
퀀텀 바이오파마 (NASDAQ:QNTM)는 2025년 1월 14일 오전 10시에 Upstream, MERJ Exchange 시장 및 글로벌 증권 거래 앱에 이중 상장한다고 발표했습니다. 신경퇴행성, 대사, 알코올 남용 장애 치료 개발에 집중하는 이 회사는 Nasdaq, Canadian Securities Exchange 및 프랑크푸르트 증권거래소에 대한 상장도 유지합니다.
Upstream 플랫폼은 20시간 동안 운영되며, 투명한 주문 장부를 갖춘 실시간 거래와 정산을 제공합니다. 비미국 투자자는 KYC 검증을 완료한 후 Upstream 앱을 통해 QNTM 주식에 접근할 수 있습니다. 거래는 기존 주주가 판매 제안을 하는 즉시 시작됩니다.
CEO 지잔 사이드(Zeeshan Saeed)는 이중 상장이 가치를 더하고 유동성을 높이며 글로벌 투자자 기반을 확장하는 것을 목표로 한다고 말합니다. 미국인은 Upstream에서 증권을 예치, 구매 또는 판매하는 것이 제한됩니다.
Quantum BioPharma (NASDAQ:QNTM) annonce sa double cotation sur Upstream, un marché MERJ Exchange et une application mondiale de trading de valeurs mobilières, à partir du 14 janvier 2025 à 10h00 EST. L'entreprise, qui se concentre sur le développement de traitements pour les troubles neurodégénératifs, métaboliques et d'abus d'alcool, conservera ses cotations sur le Nasdaq, la Bourse canadienne et les marchés de Francfort.
La plateforme Upstream fonctionne 20 heures par jour, offrant un trading et une liquidation en temps réel avec des fonctionnalités de livre d'ordres transparentes. Les investisseurs non américains peuvent accéder aux actions QNTM via l'application Upstream après avoir complété la vérification KYC. Le trading commence dès qu'un actionnaire existant fait une offre de vente.
Le PDG Zeeshan Saeed déclare que cette double cotation vise à ajouter de la valeur et de la liquidité tout en élargissant leur portée à une base d'investisseurs mondiale. Les personnes vivant aux États-Unis sont interdites de déposer, d'acheter ou de vendre des valeurs mobilières sur Upstream.
Quantum BioPharma (NASDAQ:QNTM) kündigt seine doppelte Notierung an der Upstream, einem MERJ Exchange Markt und globalen Wertpapierhandels-App, ab dem 14. Januar 2025 um 10:00 Uhr EST an. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für neurodegenerative, metabolische und Alkoholmissbrauchsstörungen konzentriert, wird seine Notierungen an der Nasdaq, der Canadian Securities Exchange und den Frankfurter Börsen beibehalten.
Die Upstream-Plattform ist 20 Stunden täglich im Einsatz und bietet Echtzeit-Handel und Abwicklung mit transparenten Orderbuch-Funktionen. Nicht-US-Investoren können nach Abschluss der KYC-Verifizierung über die Upstream-App auf QNTM-Aktien zugreifen. Der Handel beginnt, sobald ein bestehender Aktionär ein Verkaufsangebot abgibt.
CEO Zeeshan Saeed erklärt, dass diese doppelte Notierung darauf abzielt, Wert und Liquidität hinzuzufügen und gleichzeitig ihre Reichweite auf eine globale Investorenbasis auszudehnen. Personen in den USA sind eingeschränkt, wenn es darum geht, Wertpapiere auf Upstream einzuzahlen, zu kaufen oder zu verkaufen.
- Expanded market access through dual listing on Upstream platform
- Increased liquidity potential for international investors
- Real-time trading and settlement capabilities on new platform
- Enhanced transparency through manipulation-resistant orderbook
- U.S. investors excluded from Upstream trading platform
- Trading commencement dependent on existing shareholders' sale offers
Quantum BioPharma Ltd. Dual Lists on Upstream's Global Securities Trading App
TORONTO, ON / ACCESSWIRE / January 14, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91)(Upstream:QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, will become available Tuesday, January 14 at 10:00am EST under the ticker symbol ‘QNTM' on Upstream, a MERJ Exchange market and global securities trading app. The dual listing on Upstream works to provide international investors around the world with streamlined access to Quantum shares using just an app. Quantum will continue to trade on the Nasdaq, Canadian Securities Exchange and Frankfurt exchanges.
Investors outside the U.S. can now deposit or trade Quantum securities by downloading Upstream from their preferred app store at https://upstream.exchange/, creating an account by tapping sign up, and completing a simple KYC identity verification. Then, investors may either deposit their Quantum shares, or fund their account with credit, debit, PayPal, USD, or USDC to buy Quantum shares. Note, U.S. persons may not deposit, buy, or sell securities on Upstream. Trading will commence when an existing shareholder places an offer for sale on Upstream establishing the first trade.
Details on the Quantum listing and deposit and trading instructions can be found at https://www.quantumbiopharma.com/investors. The Upstream market is open 7 days a week 20 hours a day, Monday to Sunday: 10:00am to 06:00am UTC+4 (1:00am to 9:00pm EST). Traders on Upstream's smart-contract powered market will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations.
Existing global (non-U.S.) shareholders may transfer their shares by opening Upstream, tapping Investor, Manage Securities, Deposit Securities, then entering the ticker symbol and the number of shares to deposit, and tapping Submit. Next, shareholders enter the brokerage firm name and brokerage account number and tap Submit. Finally, they tap Add E-Signature, sign their name on the screen using their finger, tap Done, and then tap Sign. Shareholders will receive via email an executed deposit form to submit to their current brokerage firm to initiate a withdrawal to the transfer agent. Shareholders will receive a push notification once the shares are deposited and available for trading on Upstream.
"We are excited to dual list on Upstream's next generation marketplace," says Zeeshan Saeed, CEO of Quantum. "We are adding new value and liquidity to our shareholders while expanding our company and mission to a modern, global investor-base."
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of
About Upstream
Upstream, a MERJ Exchange market (https://merj.exchange/), is a global securities trading app. Powered by Horizon's proprietary, transparency-first, matching engine, Upstream allows investors outside of the U.S. to trade securities using just an app. For more information, please visit https://upstream.exchange/. Upstream is currently accepting applications to dual list at https://upstream.exchange/getlisted.
Disclaimers
U.S. persons may not deposit, buy, or sell securities on Upstream.
This communication shall not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted. All orders for sale are non-solicited by Upstream and a user's decision to trade securities must be based on their own investment judgment.
Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company's securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com
Contact Information
Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
1-833-571-1811
SOURCE: Quantum BioPharma Ltd.
View the original press release on accesswire.com
FAQ
When will Quantum BioPharma (QNTM) start trading on Upstream?
What are the trading hours for QNTM on Upstream?
Can U.S. investors trade QNTM shares on Upstream?
How can international investors buy QNTM shares on Upstream?
What exchanges will QNTM continue to trade on besides Upstream?
